Nanexa AB
40M
Company Profile
Business description
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries.
Contact
Virdings Alle 32B
Uppsala75450
SWET: +46 18100300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
stocks
Our view on Santos after production is ramped up
Barossa at 75% capacity and Pikka undergoing commissioning.
stocks
GE Aerospace earnings: No good deed goes unpunished
We’ve raised our fair value estimate of GE Aerospace stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,210.70 | 36.50 | 0.40% |
| CAC 40 | 8,148.89 | 79.72 | 0.99% |
| DAX 40 | 24,856.47 | 295.49 | 1.20% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,150.05 | 11.96 | 0.12% |
| HKSE | 26,797.07 | 167.11 | 0.63% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,851.87 | 162.98 | 0.30% |
| NZX 50 Index | 13,498.57 | 58.30 | -0.43% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,880.30 | 35.20 | 0.40% |
| SSE Composite Index | 4,136.46 | 13.88 | 0.34% |